

Early estimates of SARS-CoV-2 Omicron variant severity based on a matched cohort study, Ontario, Canada

Ana Cecilia Ulloa, MPH, Sarah A. Buchan, PhD, Nick Daneman, MD MSc, Kevin A Brown, PhD

Affiliations

Public Health Ontario, Toronto, Canada (Ulloa, Buchan, Daneman, Brown)

Version date: December 24, 2021

Complete word count (excluding figures/captions): 634

Corresponding Author

Kevin Antoine Brown

Scientist, Public Health Ontario

Assistant Professor, University of Toronto

480 University Ave, Suite 300

Toronto, ON M5G1V2

tel: +1-416-737-1785

e-mail: kevin.brown@oahpp.ca

Abstract

While it is now evident that Omicron is rapidly replacing Delta, due to a combination of increased transmissibility and immune escape, it is less clear how the severity of Omicron compares to Delta. In Ontario, we sought to examine hospitalization and death associated with Omicron, as compared to matched cases infected with Delta. We conducted a matched cohort study, considering time to hospitalization or death as the outcome, and analyzed with a Cox proportional hazards model. Cases were matched on age, gender, and onset date, while vaccine doses received and time since vaccination were included as adjustment variables. We identified 6,314 Omicron cases that met eligibility criteria, of which 6,312 could be matched with at least one Delta case (N=8,875) based on age, gender, and onset date. There were 21 (0.3%) hospitalizations and 0 (0%) deaths among matched Omicron cases, compared to 116 (2.2%) hospitalizations and 7 (0.3%) deaths among matched Delta cases. The adjusted risk of hospitalization or death was 54% lower (HR=0.46, 95%CI: 0.27, 0.77) among Omicron cases compared to Delta cases. While severity may be reduced, the absolute number of hospitalizations and impact on the healthcare system could still be significant due to the increased transmissibility of Omicron.

Introduction

The WHO designated Omicron as a Variant of Concern on November 26, 2021.¹ Omicron has more than 30 mutations in the spike protein, and it is now evident that Omicron is rapidly replacing Delta² due to a combination of increased transmissibility and immune escape. It is less clear how the severity of Omicron compares. Early data from South Africa suggests that Omicron may be less severe than prior lineages;³ however, the low average age, extent of previous infection, and low vaccination rates impact generalizability to certain other countries. In Ontario, we sought to examine hospitalization and death rates associated with Omicron, as compared to matched patients infected with Delta.

Methods

We conducted a retrospective population-wide matched cohort study of patients infected with Omicron and Delta variants, using Ontario's Public Health Case and Contact Management Solution (CCM), a database containing all diagnosed SARS-CoV-2 infections, linked to Ontario Ministry of Health's COVaxON application, containing all COVID-19 vaccination records in the province. Cases were included if onset occurred between November 22 and December 17, 2021, based on the date of the first Omicron case reported in Ontario. Case onset date was defined by symptom onset, or for asymptomatic cases, specimen collection. Cases were excluded if they were missing onset date, age or sex or were hospital-acquired. Omicron cases included those identified by whole genome sequencing (WGS), S-gene target failure (SGTF) with cycle threshold ≤ 30 before December 13 (date of 50% Omicron prevalence),² and any SGTF on or after December 13. Delta cases included those detected by WGS, those with amplification of the S-gene, and all cases not identified as Omicron prior to December 3 (date of 5% Omicron prevalence).² Omicron cases were matched to Delta cases using up to 2:1 matching on age (± 5 years), gender, and onset date (± 7 days). Cox proportional hazards models accounting for clustering within matched sets were used to determine the hazards of hospitalization-or-death for Omicron compared to Delta cases. Covariates in adjusted analyses included vaccine doses received (0-3), time since most recent dose (>14 days to <3 months, 3-6 months, ≥ 6 months) and region. Stratified analyses were performed to evaluate differences in risk by age group (<60 and ≥ 60 years).

Results

We identified 6,314 Omicron cases that met eligibility criteria, of which 6,312 were matched with ≥ 1 Delta case (N=8,875) based on age, gender, and onset date (Table). There were 21 (0.3%) hospitalizations and 0 (0%) deaths among matched Omicron cases, compared to 116 (2.2%) hospitalizations and 7 (0.3%) deaths among matched Delta cases. The risk of hospitalization or death was 68% lower (hazard ratio, HR=0.32, 95%CI: 0.20-0.51) in Omicron compared to Delta cases (Figure). After adjustment for vaccination status, the risk of hospitalization or death was 54% lower (HR=0.46, 95%CI: 0.27-0.77). Stratified estimates by age were similar (HR_{<60}=0.30, 95%CI: 0.16-0.57, HR _{≥ 60} =0.55, 95%CI: 0.28-1.06).

Discussion

In this matched study of over 6,000 Omicron cases, we found that the risk of hospitalization was 54% lower for Omicron cases versus Delta cases. Our results align with findings from South Africa, Scotland and England, all of which have demonstrated substantial decreases in risk of hospitalization associated with Omicron.³⁻⁵ One early hypothesis for increased transmissibility with decreased severity is the increased replication in the bronchi but decreased replication in lung parenchyma.⁶

Our study has some limitations, in particular the short follow-up duration and potential misclassification due to incidental findings from hospital admission screening, and incomplete public health follow-up as incidence increased. However, Omicron appears to demonstrate lower disease severity. While severity may be reduced, the absolute number of hospitalizations and impact on the healthcare system is likely to be significant due to the increased transmissibility of Omicron.

References

1. Callaway E. Heavily mutated Omicron variant puts scientists on alert. *Nature*. 2021;600(7887):21-21. doi:10.1038/d41586-021-03552-w
2. *Early Dynamics of Omicron in Ontario, November 1 to December 16, 2021 Published: December 21, 2021*. Public Health Ontario; 2021:5. Accessed December 24, 2021. <https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-early-dynamics-omicron-ontario-epi-summary.pdf>

3. Wolter N, Jassat W, Walaza S, et al. *Early Assessment of the Clinical Severity of the SARS-CoV-2 Omicron Variant in South Africa*. Infectious Diseases (except HIV/AIDS); 2021. doi:10.1101/2021.12.21.21268116
4. Ferguson N. *Report 50: Effectiveness of SARS-CoV-2 Vaccines in England in 2021: A Whole Population Survival Analysis*. Imperial College London; 2021. doi:10.25561/93035
5. Sheikh A, Kerr S, Woolhouse M, McMenamin J, Robertson C. *Severity of Omicron Variant of Concern and Vaccine Effectiveness against Symptomatic Disease: National Cohort with Nested Test Negative Design Study in Scotland.*; 2021.
6. HKUMed finds Omicron SARS-CoV-2 can infect faster and better than Delta in human bronchus but with less severe infection in lung. Accessed December 24, 2021. <https://www.med.hku.hk/en/news/press/20211215-omicron-sars-cov-2-infection>

Figures and Tables

Table. Demographic characteristics of matched SARS-CoV-2 Delta variant and Omicron variant cases (N, %).

	Delta	Omicron
	N=8,875	N=6,312
Age; median (p25, p75)	30.0 (14.0, 44.0)	28.0 (20.0, 42.0)
Sex		
Female	4,502 (50.7)	3,188 (50.5)
Male	4,363 (49.2)	3,118 (49.4)
Other	10 (0.1)	8 (0.1)
Vaccination status		
0 doses	3,896 (43.9)	1,080 (17.1)
1 dose		
>14d to 3 months	445 (5.0)	188 (3.0)
3 to 6 months	54 (0.6)	21 (0.3)
6+ months	57 (0.6)	21 (0.3)
2 doses		
>14d to 3 months	259 (2.9)	256 (4.1)
3 to 6 months	2,862 (32.3)	3,467 (54.9)
6+ months	1,179 (13.3)	1,127 (17.9)
3 doses		
>14d to 3 months	115 (1.3)	149 (2.4)
3 to 6 months	8 (0.1)	4 (0.1)
6+ months	0 (0.0)	0 (0.0)
Outcomes		
Deaths	7 (0.3)	0 (0.0)
Hospitalization or death	116 (2.2)	21 (0.3)

Note: d, days; p25, 25th percentile, p75, 75th percentile.

Figure. SARS-CoV-2 associated hospitalization or death among matched Omicron variant (N=6,312, green line) and Delta variant cases (N=8,875, orange line) cases as a function of days since onset. Date of onset was defined as symptom onset date, falling back to first positive specimen collection date.

